Patient- and Clinician-Reported Meaningfulness of Treatment-Related Change Following Investigational Sirolimus Topical Gel 3.9% in Microcystic Lymphatic Malformations: Qualitative Findings From the Phase 3 SELVA Trial Show Clinical Benefit and High Treatment Satisfaction
SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s823
DOI: 10.25251/3ggsk832 ↗Kurz gefasst
Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Maria Gnarra Beuthe und 18 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Microcystic lymphatic malformations (mLM) are lifelong, rare, and serious vascular anomalies associated with substantial physical and psychosocial morbidity. Currently, no FDA-approved therapeutics exist; disease management involves invasive procedures (surgery, sclerotherapy, laser) and off-label oral and topical sirolimus, all associated with inconsistent results. Sirolimus topical gel 3.9%, developed on the QTORIN™ platform to address these unmet therapeutic needs, was evaluated in the pivotal Phase 3 SELVA trial. Consistent with regulatory guidance emphasizing the patient voice in drug development, an embedded qualitative interview study characterized patient/caregiver perspectives of mLM and the meaningfulness of treatment-related change.
Objective
To contextualize clinical trial efficacy endpoints through the patient/caregiver experience and evaluate treatment satisfaction following topical sirolimus 3.9% gel.
Methods
Semi-structured entry (baseline) and exit (Day 168) interviews were conducted with trial participants and/or their caregivers (for participants
Zitieren
APA
Beuthe, M. G., Kahle, K., Treat, J., Adams, D., Cohen-Cutler, S., Kelly, M., Tollefson, M., Theos, A., Martini, J., Kaupinen, W., Cook, E., Zaenglein, A., Ricci, K., Nieman, E., Iacobas, I., White, M., Swaminathan, N., Hudgens, S., & Teng, J. (2026). Patient- and Clinician-Reported Meaningfulness of Treatment-Related Change Following Investigational Sirolimus Topical Gel 3.9% in Microcystic Lymphatic Malformations: Qualitative Findings From the Phase 3 SELVA Trial Show Clinical Benefit and High Treatment Satisfaction. SKIN The Journal of Cutaneous Medicine, 10(6), s823. https://doi.org/10.25251/3ggsk832
Vancouver
Beuthe MG, Kahle K, Treat J, Adams D, Cohen-Cutler S, Kelly M, et al. Patient- and Clinician-Reported Meaningfulness of Treatment-Related Change Following Investigational Sirolimus Topical Gel 3.9% in Microcystic Lymphatic Malformations: Qualitative Findings From the Phase 3 SELVA Trial Show Clinical Benefit and High Treatment Satisfaction. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s823. doi:10.25251/3ggsk832
BibTeX
@article{Beuthe2026,
author = {Beuthe, Maria Gnarra and Kahle, Kristen and Treat, James and Adams, Denise and Cohen-Cutler, Sally and Kelly, Michael and Tollefson, Megha and Theos, Amy and Martini, Jeffrey and Kaupinen, Wes and Cook, Emily and Zaenglein, Andrea and Ricci, Kiersten and Nieman, Elizabeth and Iacobas, Ionela and White, Michael and Swaminathan, Neeraja and Hudgens, Stacie and Teng, Joyce},
title = {Patient- and Clinician-Reported Meaningfulness of Treatment-Related Change Following Investigational Sirolimus Topical Gel 3.9% in Microcystic Lymphatic Malformations: Qualitative Findings From the Phase 3 SELVA Trial Show Clinical Benefit and High Treatment Satisfaction},
journal = {SKIN The Journal of Cutaneous Medicine},
year = {2026},
volume = {10},
number = {6},
pages = {s823},
doi = {10.25251/3ggsk832}
}
EUVIMED